H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Aptose Biosciences (APTO – Research Report) today and set a price target of $12.00. The company’s shares closed last Tuesday at $0.71, close to its 52-week low of $0.71.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -29.1% and a 21.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Applied Genetic Technologies, and Lineage Cell Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aptose Biosciences with a $7.47 average price target.
Aptose Biosciences’ market cap is currently $66.71M and has a P/E ratio of -1.06.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of APTO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
Read More on APTO:
- Denny’s (DENN) Gets a Hold Rating from Wedbush
- Cirrus Logic (CRUS) Receives a Buy from Needham
- Analysts Offer Insights on Healthcare Companies: Rigel (RIGL), Sarepta Therapeutics (SRPT) and Cytosorbents (CTSO)
- H.C. Wainwright Thinks EMX Royalty’s Stock is Going to Recover
- Cowen & Co. Thinks Daseke’s Stock is Going to Recover